Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Meeting report: Global vaccine and immunization research forum, 2018.

Dull P, Friede M, Hwang A, Hall BF.

Vaccine. 2019 Dec 10;37(52):7519-7526. doi: 10.1016/j.vaccine.2019.10.011. Epub 2019 Oct 14.

2.

Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development.

Avci F, Berti F, Dull P, Hennessey J, Pavliak V, Prasad AK, Vann W, Wacker M, Marcq O.

mSphere. 2019 Sep 25;4(5). pii: e00520-19. doi: 10.1128/mSphere.00520-19.

3.

Hospital readmission in persons with dementia: A systematic review.

Ma C, Bao S, Dull P, Wu B, Yu F.

Int J Geriatr Psychiatry. 2019 Aug;34(8):1170-1184. doi: 10.1002/gps.5140. Epub 2019 May 20.

PMID:
31087373
4.

HPV single-dose vaccination: Impact potential, evidence base and further evaluation.

Stanley M, Dull P.

Vaccine. 2018 Aug 6;36(32 Pt A):4759-4760. doi: 10.1016/j.vaccine.2018.02.076. Epub 2018 May 10. No abstract available.

5.

Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy.

Madhi SA, Koen A, Cutland CL, Jose L, Govender N, Wittke F, Olugbosi M, Sobanjo-Ter Meulen A, Baker S, Dull PM, Narasimhan V, Slobod K.

Clin Infect Dis. 2017 Nov 13;65(11):1897-1904. doi: 10.1093/cid/cix666.

6.

Combination vaccine strategies to prevent enteric infections.

Walker R, Dull P.

Vaccine. 2017 Dec 14;35(49 Pt A):6790-6792. doi: 10.1016/j.vaccine.2017.06.076. Epub 2017 Jul 10.

7.

Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].

Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ; European Men B Vaccine Study Group.

Vaccine. 2017 May 31;35(24):3279. doi: 10.1016/j.vaccine.2017.04.081. Epub 2017 May 5. No abstract available.

8.

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.

Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ; European Men B Vaccine Study Group.

Vaccine. 2017 Jan 5;35(2):395-402. doi: 10.1016/j.vaccine.2016.11.009. Epub 2016 Nov 30. Erratum in: Vaccine. 2017 May 31;35(24):3279.

9.

A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.

Read RC, Dull P, Bai X, Nolan K, Findlow J, Bazaz R, Kleinschmidt A, McCarthy M, Wang H, Toneatto D, Borrow R.

Vaccine. 2017 Jan 11;35(3):427-434. doi: 10.1016/j.vaccine.2016.11.071. Epub 2016 Nov 29.

10.

Response.

Berry SM, Petzold EA, Dull P, Thielman NM, Cunningham CK, McClain MT, Hoover DL, Russell J, Griffiss JM, Woods CW.

Clin Trials. 2016 Oct;13(5):568-9. doi: 10.1177/1740774516654446. Epub 2016 Jun 30. No abstract available.

PMID:
27365016
11.

Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.

Madhi SA, Cutland CL, Jose L, Koen A, Govender N, Wittke F, Olugbosi M, Meulen AS, Baker S, Dull PM, Narasimhan V, Slobod K.

Lancet Infect Dis. 2016 Aug;16(8):923-34. doi: 10.1016/S1473-3099(16)00152-3. Epub 2016 Apr 29.

PMID:
27139805
12.

Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial.

Donders GG, Halperin SA, Devlieger R, Baker S, Forte P, Wittke F, Slobod KS, Dull PM.

Obstet Gynecol. 2016 Feb;127(2):213-21. doi: 10.1097/AOG.0000000000001190.

PMID:
26942345
13.

A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.

Leroux-Roels G, Maes C, Willekens J, De Boever F, de Rooij R, Martell L, Bedell L, Wittke F, Slobod K, Dull P.

Vaccine. 2016 Apr 4;34(15):1786-91. doi: 10.1016/j.vaccine.2016.02.044. Epub 2016 Mar 5.

PMID:
26928074
14.

Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.

Heyderman RS, Madhi SA, French N, Cutland C, Ngwira B, Kayambo D, Mboizi R, Koen A, Jose L, Olugbosi M, Wittke F, Slobod K, Dull PM.

Lancet Infect Dis. 2016 May;16(5):546-555. doi: 10.1016/S1473-3099(15)00484-3. Epub 2016 Feb 8.

15.

A response adaptive randomization platform trial for efficient evaluation of Ebola virus treatments: A model for pandemic response.

Berry SM, Petzold EA, Dull P, Thielman NM, Cunningham CK, Corey GR, McClain MT, Hoover DL, Russell J, Griffiss JM, Woods CW.

Clin Trials. 2016 Feb;13(1):22-30. doi: 10.1177/1740774515621721. Epub 2016 Jan 14.

16.

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age.

Snape MD, Voysey M, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Kieninger D, Prymula R, Dull PM, Kohl I, Barone M, Wang H, Toneatto D, Pollard AJ; European MenB Vaccine Study Group.

Pediatr Infect Dis J. 2016 Apr;35(4):e113-23. doi: 10.1097/INF.0000000000001056.

PMID:
26756390
17.

Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants: Results of a Phase 3b, Randomized, Open-label Trial.

Block SL, Shepard J, Garfield H, Xie F, Han L, Dull PM, Smolenov I.

Pediatr Infect Dis J. 2016 Feb;35(2):e48-59. doi: 10.1097/INF.0000000000000965.

PMID:
26479973
18.

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.

Nolan T, O'Ryan M, Wassil J, Abitbol V, Dull P.

Vaccine. 2015 Aug 26;33(36):4437-45. doi: 10.1016/j.vaccine.2015.06.011. Epub 2015 Jul 15. Review.

19.

Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children.

Vesikari T, Prymula R, Merrall E, Kohl I, Toneatto D, Dull PM.

Vaccine. 2015 Jul 31;33(32):3850-8. doi: 10.1016/j.vaccine.2015.06.079. Epub 2015 Jun 30.

PMID:
26141011
20.

Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in Adolescents.

Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Han L, Smolenov I, Dull P.

Pediatr Infect Dis J. 2015 Oct;34(10):e264-78. doi: 10.1097/INF.0000000000000822.

PMID:
26135245
21.

Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.

Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Graña MG, Heijnen E, Smolenov I, Dull PM.

Hum Vaccin Immunother. 2015;11(6):1507-17. doi: 10.1080/21645515.2015.1029686.

22.

Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.

McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Yu LM, Toneatto D, D'Agostino D, Dull PM, Pollard AJ.

CMAJ. 2015 Apr 21;187(7):E215-E223. doi: 10.1503/cmaj.141200. Epub 2015 Mar 23.

23.

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.

Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I.

Vaccine. 2015 May 15;33(21):2500-10. doi: 10.1016/j.vaccine.2015.03.001. Epub 2015 Mar 17.

PMID:
25795256
24.

Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.

Block SL, Christensen S, Verma B, Xie F, Keshavan P, Dull PM, Smolenov I.

Vaccine. 2015 Apr 27;33(18):2175-82. doi: 10.1016/j.vaccine.2015.02.049. Epub 2015 Mar 2.

PMID:
25744224
25.

Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection.

McIntosh ED, Carey V, Toneatto D, Dull P, Wassil J.

Ther Adv Vaccines. 2015 Jan;3(1):13-23. doi: 10.1177/2051013614557477. Review.

26.

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).

Esposito S, Prymula R, Zuccotti GV, Xie F, Barone M, Dull PM, Toneatto D.

Hum Vaccin Immunother. 2014;10(7):2005-14. doi: 10.4161/hv.29218.

27.

A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).

Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, Dull PM.

Hum Vaccin Immunother. 2014;10(7):1993-2004. doi: 10.4161/hv.28666.

28.

Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.

Lee HJ, Chung MH, Kim WJ, Hong YJ, Choi KM, Lee J, Oh CE, Welsch JA, Kim KH, Hong KB, Dagnew AF, Bock H, Dull PM, Odrljin T.

Int J Infect Dis. 2014 Nov;28:204-10. doi: 10.1016/j.ijid.2014.06.008. Epub 2014 Oct 12.

29.

Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.

Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, Bazaz R, Ganguli A, Havelock T, Neal KR, Okike IO, Morales-Aza B, Patel K, Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MC, Toneatto D, Wang H, McCarthy M, Dull PM, Borrow R.

Lancet. 2014 Dec 13;384(9960):2123-31. doi: 10.1016/S0140-6736(14)60842-4. Epub 2014 Aug 18.

PMID:
25145775
30.

Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.

Tregnaghi M, Lopez P, Stamboulian D, Graña G, Odrljin T, Bedell L, Dull PM.

Int J Infect Dis. 2014 Sep;26:22-30. doi: 10.1016/j.ijid.2014.03.1390. Epub 2014 Jun 26.

31.

Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.

Baxter R, Reisinger K, Block SL, Percell S, Odrljin T, Dull PM, Smolenov I.

Pediatr Infect Dis J. 2014 Nov;33(11):1169-76. doi: 10.1097/INF.0000000000000438.

PMID:
24911896
32.

Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.

McQuaid F, Snape MD, John TM, Kelly S, Robinson H, Houlden J, Voysey M, Toneatto D, Kitte C, Dull PM, Pollard AJ.

Pediatr Infect Dis J. 2014 Jul;33(7):760-6. doi: 10.1097/INF.0000000000000327.

PMID:
24722351
33.

Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.

Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P.

J Pediatr. 2014 Jun;164(6):1409-15.e4. doi: 10.1016/j.jpeds.2014.02.025. Epub 2014 Mar 20.

PMID:
24657122
34.

Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.

Abdelnour A, Silas PE, Lamas MR, Aragón CF, Chiu NC, Chiu CH, Acuña TH, Castrejón Tde L, Izu A, Odrljin T, Smolenov I, Hohenboken M, Dull PM.

Vaccine. 2014 Feb 12;32(8):965-72. doi: 10.1016/j.vaccine.2013.12.034. Epub 2014 Jan 4.

PMID:
24397906
35.

A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.

O'Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM.

Drugs. 2014 Jan;74(1):15-30. doi: 10.1007/s40265-013-0155-7. Review.

36.

Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.

Nolan TM, Nissen MD, Naz A, Shepard J, Bedell L, Hohenboken M, Odrljin T, Dull PM.

Hum Vaccin Immunother. 2014;10(2):280-9. doi: 10.4161/hv.27051. Epub 2013 Nov 12.

37.

Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.

Snape MD, Saroey P, John TM, Robinson H, Kelly S, Gossger N, Yu LM, Wang H, Toneatto D, Dull PM, Pollard AJ.

CMAJ. 2013 Oct 15;185(15):E715-24. doi: 10.1503/cmaj.130257. Epub 2013 Sep 23.

38.

Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants.

Madhi SA, Dangor Z, Heath PT, Schrag S, Izu A, Sobanjo-Ter Meulen A, Dull PM.

Vaccine. 2013 Aug 28;31 Suppl 4:D52-7. doi: 10.1016/j.vaccine.2013.02.029. Review.

PMID:
23973347
39.

Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.

Snape MD, Philip J, John TM, Robinson H, Kelly S, Gossger N, Yu LM, Kittel C, Toneatto D, Dull PM, Pollard AJ.

Pediatr Infect Dis J. 2013 Oct;32(10):1116-21. doi: 10.1097/INF.0b013e31829cfff2.

PMID:
23958808
40.

Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.

Santolaya ME, O'Ryan M, Valenzuela MT, Prado V, Vergara RF, Muñoz A, Toneatto D, Graña G, Wang H, Dull PM.

Hum Vaccin Immunother. 2013 Nov;9(11):2304-10. Epub 2013 Jun 28.

41.

Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom.

Blanchard-Rohner G, Snape MD, Kelly DF, O'Connor D, John T, Kibwana E, Parks H, Ford K, Dull PM, Pollard AJ.

Pediatr Infect Dis J. 2013 Jul;32(7):768-76. doi: 10.1097/INF.0b013e318292f425.

PMID:
23538521
42.

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.

Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group.

Lancet. 2013 Mar 9;381(9869):825-35. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

PMID:
23324563
43.

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK.

Vaccine. 2013 Feb 4;31(7):1113-6. doi: 10.1016/j.vaccine.2012.12.022. Epub 2012 Dec 20.

PMID:
23261039
44.

Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.

Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM.

Pediatr Infect Dis J. 2013 Apr;32(4):e170-7. doi: 10.1097/INF.0b013e318279ac38.

PMID:
23114372
45.

Polysaccharide-protein conjugate vaccination induces antibody production but not sustained B-cell memory in the human nasopharyngeal mucosa.

Clarke ET, Williams NA, Dull PM, Findlow J, Borrow R, Finn A, Heyderman RS.

Mucosal Immunol. 2013 Mar;6(2):288-96. doi: 10.1038/mi.2012.70. Epub 2012 Jul 18.

PMID:
22806100
46.

Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.

Dull PM, McIntosh ED.

Vaccine. 2012 May 30;30 Suppl 2:B18-25. doi: 10.1016/j.vaccine.2012.01.062. Review.

PMID:
22607895
47.

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.

Klein NP, Shepard J, Bedell L, Odrljin T, Dull P.

Vaccine. 2012 Jun 6;30(26):3929-36. doi: 10.1016/j.vaccine.2012.03.080. Epub 2012 Apr 10.

PMID:
22504039
48.

Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations.

Khatami A, Snape MD, Davis E, Layton H, John T, Yu LM, Dull PM, Gill CJ, Odrjlin T, Dobson S, Halperin SA, Langley JM, McNeil SA, Pollard AJ.

Vaccine. 2012 Apr 16;30(18):2831-8. doi: 10.1016/j.vaccine.2012.02.046. Epub 2012 Mar 3.

PMID:
22394992
49.

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ; European MenB Vaccine Study Group.

JAMA. 2012 Feb 8;307(6):573-82. doi: 10.1001/jama.2012.85.

PMID:
22318278
50.

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.

Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, Dull PM; V72P10 Meningococcal B Adolescent Vaccine Study group.

Lancet. 2012 Feb 18;379(9816):617-24. doi: 10.1016/S0140-6736(11)61713-3. Epub 2012 Jan 18. Erratum in: Lancet. 2015 May 2;385(9979):1728.

PMID:
22260988

Supplemental Content

Support Center